Presentation is loading. Please wait.

Presentation is loading. Please wait.

Antitumor effects of celastrol in vitro and in vivo.

Published byBirgit Jonasson Modified over 5 years ago

Similar presentations

Presentation on theme: "Antitumor effects of celastrol in vitro and in vivo."— Presentation transcript:

1 Antitumor effects of celastrol in vitro and in vivo.
Antitumor effects of celastrol in vitro and in vivo. A, celastrol inhibits pancreatic cancer cell proliferation by MTS assay. B, celastrol (5 μmol/L) induces apoptosis by Annexin V staining. C, antitumor activity of celastrol against Panc-1 xenograft model. Arrows, dosing time. D to F, celastrol inhibits tumor growth in RIP1-Tag2 transgenic mouse model with pancreatic islet cell carcinoma. D, comparison of weights and volumes of the primary pancreatic islet cell carcinoma in each group when the RIP1-Tag2 mice were sacrificed at week 12. E, comparison of the metastatic tumor weights and volumes in each group when the RIP1-Tag2 mice were sacrificed at week 12. F, survival rate of the RIP1-Tag2 mice for each drug treatment group. Tao Zhang et al. Mol Cancer Ther 2008;7: ©2008 by American Association for Cancer Research

Download ppt "Antitumor effects of celastrol in vitro and in vivo."

Similar presentations

BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden

BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden
Cell Physiol Biochem 2016;38: DOI: /

Cell Physiol Biochem 2016;38: DOI: /
A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.
Antitumor activity of BAY in patient-derived tumor models.

Antitumor activity of BAY in patient-derived tumor models.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.
Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.

Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.
CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.
Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.
TFAP2A knockdown inhibits tumor growth in vivo.

TFAP2A knockdown inhibits tumor growth in vivo.
Antitumor immunity caused by DS-8201a.

Antitumor immunity caused by DS-8201a.
Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.
PX-478 directly radiosensitizes tumor cells in vitro.

PX-478 directly radiosensitizes tumor cells in vitro.
PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC
Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

Similar presentations

Ads by Google